FRAMINGHAM, Mass.--(BUSINESS WIRE)--Variantyx, a leader in molecular diagnostics, announced today that it has secured an additional $36 million in funding from its portfolio of investors which includes Peregrine Ventures, Pitango HealthTech, New Era Capital Partners and Bosch Ventures. The company, a technology-driven provider of advanced genomic testing for genetic disorders, reproductive health and precision oncology markets has seen a rapid increase in test volumes in the first quarter of 2024, further expanding its market share.

马萨诸塞州弗雷明汉市。-（商业新闻短讯）--分子诊断领域的领导者Variantyx今天宣布，它已经从其投资者组合中获得了3600万美元的额外资金，其中包括Peregrine Ventures，Pitango HealthTech，New Era Capital Partners和Bosch Ventures。该公司是一家以技术为驱动的针对遗传疾病、生殖健康和精准肿瘤学市场的先进基因组测试提供商，2024年第一季度的测试量迅速增加，进一步扩大了其市场份额。

The additional investment, which brings the total amount invested in Variantyx to over $125 million, will fund additional technological and commercial expansion, enabling the company to capitalize on the shifting market, seizing the opportunity to provide cutting-edge, genome-based care to a larger number of patients while maintaining strong unit economics and building significant value..

这项额外投资使Variantyx的投资总额超过1.25亿美元，将为额外的技术和商业扩张提供资金，使该公司能够利用不断变化的市场，抓住机会为更多患者提供尖端的基于基因组的护理，同时保持强大的单位经济性并创造巨大的价值。。

“It’s clear that the current shift away from panel and exome-based testing to whole genome testing benefits patients, providers and payers alike,” said Christine Stanley, Variantyx’s Chief Director of Clinical Genomics. “As a pioneer in clinically-accredited, genome-based testing with tens of thousands of genomes sequenced to date, Variantyx is well-positioned to maintain its leadership in genomic diagnostics with on-going innovation of new genome analysis technologies, providing real improvements in patient outcomes to an increasingly larger subset of the population.”.

Variantyx临床基因组学首席总监克里斯蒂娜·斯坦利（ChristineStanley）说：“很明显，目前从基于面板和外显子组的测试转向全基因组测试，对患者、提供者和付款人都有好处。”。“作为临床认可的基于基因组的测试的先驱，迄今已测序了数万个基因组，Variantyx处于有利地位，可以通过不断创新的新基因组分析技术来保持其在基因组诊断方面的领先地位，从而为越来越多的人群提供真正的患者预后改善。”。

“The funding demonstrates continued trust and confidence in our ability to deliver on the long-term goals of the company,” said Haim Neerman, CEO of Variantyx. “The additional commercial expansion enabled by this newest investment will help further accelerate our growth to meet the market demand.”

Variantyx首席执行官哈伊姆·尼尔曼（HaimNeerman）表示：“这笔资金显示出我们对实现公司长期目标的能力的持续信任和信心。”。“这项最新投资带来的额外商业扩张将有助于进一步加速我们的增长，以满足市场需求。”

About Variantyx

Variantyx

Variantyx is an award-winning, technology-driven molecular diagnostics company providing disruptive solutions for the genetic disorders, reproductive health, and precision oncology markets. The proprietary whole genome analysis platforms developed by Variantyx allow clinicians to better understand a person’s genetic makeup, leading to unmatched diagnostic capabilities and improved personalized treatment recommendations.

Variantyx是一家屡获殊荣、技术驱动的分子诊断公司，为遗传疾病、生殖健康和精准肿瘤学市场提供颠覆性解决方案。Variantyx开发的专有全基因组分析平台使临床医生能够更好地了解一个人的基因组成，从而产生无与伦比的诊断能力和改进的个性化治疗建议。

For more information, please visit www.variantyx.com..

有关更多信息，请访问www.variantyx.com。。